IL1B and periodontitis: Following the 24 months of treatment with the regimen, the regimen was found to directionally reduce bacterial amount and diversity while also statistically significantly reducing critical biomarkers (IL-1β, MMP-1, MMP-9) associated with inflammation and periodontitis.